The effect of the lipophilicity of a carrier on human skin penetration of an extremely lipophilic active model substance was evaluated by using Franz type diffusion cells. Oil-in-water model emulsions containing different amounts of the oily phase were prepared, and Myritol® PC (M-PC) was selected as lipophilic marker component of the oily phase. The penetrated amounts of the lipophilic model substance salicyloyl phytosphingosine (SP) were determined by high-performance liquid chromatography with ultraviolet detection, while M-PC was detected using gas chromatography coupled with mass spectrometry. It has been ascertained that the amount of the lipid phase within the emulsion influenced the penetration profile of the active ingredient SP. The emulsion containing the lowest proportion of the lipid phase provides the best conditions for SP penetration. Surprisingly, the penetration behavior of M-PC was influenced by the oily phase in the same way. Regarding the M-PC and the SP penetration profiles from each emulsion, a solvent drag mechanism can be assumed whereby M-PC acts as penetration enhancer. In conclusion, the penetration rate of the active ingredient SP and the marker component M-PC are in reverse proportion to the oil content of the formulations. The lipophilicity of SP and M-PC, their solubility and their thermodynamic activity within the vehicle could have an effect on their penetration behavior. Additionally, M-PC has the property to enhance the penetration rates of extremely lipophilic substances even at low concentrations.

Keywords:
Human skin penetration, Lipophilic drug, Vehicle lipophilicity, High-performance liquid chromatography with ultraviolet detection, Gas chromatography coupled with mass spectrometry, Salicyloyl phytosphingosine, Myritol® PC, Oil-in-water emulsion, Solvent drag
1.
Jacobi U, Tassopoulos T, Surber C, Lademann J: Cutaneous distribution and localization of dyes affected by vehicles all with different lipophilicity. Arch Dermatol Res 2006;297:303-310.
2.
Schwarb FP, Gabard B, Rufli T, Surber C: Percutaneous absorption of salicylic acid in man after topical administration of three different formulations. Dermatology 1999;198:44-51.
3.
Motlagh L, Lange S, Polak G, Kalhoelfer V, Göbel A, Wohlrab J, Neubert RHH: Penetration studies of active model substances from an O/W emulsion - influence of the lipophilicity of the formulation in human skin. IFSCC Magazine 2012;15:175-183.
4.
Heuschkel S, Wohlrab J, Schmaus G, Neubert RH: Modulation of dihydroavenanthramide D release and skin penetration by 1,2-alkanediols. Eur J Pharm Biopharm 2008;70:239-247.
5.
SciFinderScholar TM2006. Calculated using Advanced Chemistry Development (ACD/Labs) software v11.02. 1994-2012 ACD/Labs (accessed September 5, 2012).
6.
MarvinSketch 5.3.8. Chemaxon Ltd. 2010. http://www.chemaxon.com.
7.
Farwick M, Watson RE, Rawlings AV, Wollenweber U, Lersch P, Bowden JJ, Bastrilles JY, Griffiths CE: Salicyloyl-phytosphingosine: a novel agent for the repair of photoaged skin. Int J Cosmet Sci 2007;29:319-329.
8.
Kim S, Hong I, Hwang JS, Choi JK, Rho HS, Kim DH, Chang I, Lee SH, Lee MO: Phytosphingosine stimulates the differentiation of human keratinocytes and inhibits TPA-induced inflammatory epidermal hyperplasia in hairless mouse skin. Mol Med 2006;12:17-24.
9.
Neubert R, Bendas C, Wohlrab W, Gienau B, Furst W: A multilayer membrane system for modeling drug penetration into skin. Int J Pharm 1991;75:89-94.
10.
Product Information Myritol® PC. Düsseldorf, Cognis GmbH, 2004.
11.
Franz TJ: Percutaneous absorption - on the relevance of in vitro data. J Invest Dermatol 1975;64:190-195.
12.
Lee CK, Uchida T, Kitagawa K, Yagi A, Kim NS, Goto S: Relationship between lipophilicity and skin permeability of various drugs from an ethanol/water/lauric acid system. Biol Pharm Bull 1994;17:1421-1424.
13.
Wiechers JW: Optimizing skin delivery of active ingredients from emulsions from theory to practice; in Rosen MR (ed): Delivery System Handbook for Personal Care and Cosmetic Products. Norwich, Andrew, 2005, pp 409-436.
14.
Le VH, Lippold BC: The influence of physico-chemical properties of homologous nicotinic acid esters on the permeability and maximum flux through an octanol membrane. Int J Pharm 1998;163:11-22.
15.
Guy R, Hadgraft J: Physicochemical aspects of percutaneous penetration and its enhancement. Pharm Res 1988;5:753-758.
16.
Tayar NE, Tsai R-S, Testa B, Carrupt P-A, Hansch C, Leo A: Percutaneous penetration of drugs: a quantitative structure-permeability relationship study. J Pharm Sci 1991;80:744-749.
17.
Chatelain E, Gabard B, Surber C: Skin penetration and sun protection factor of five UV filters: effect of the vehicle. Skin Pharmacol Appl Skin Physiol 2003;16:28-35.
18.
Schneider I-M, Dobner B, Neubert R, Wohlrab W: Evaluation of drug penetration into human skin ex vivo using branched fatty acids and propylene glycol. Int J Pharm 1996;145:187-196.
19.
Bendas B, Schmalfuss U, Neubert R: Influence of propylene glycol as cosolvent on mechanisms of drug transport from hydrogels. Int J Pharm 1995;116:19-30.
20.
Cornwell PA, Tubek J, van Gompel HAHP, Little CJ, Wiechers JW: Glyceryl monocaprylate/caprate as a moderate skin penetration enhancer. Int J Pharm 1998;171:243-255.
21.
Engelbrecht TN, Schroeter A, Hauss T, Neubert RHH: Lipophilic penetration enhancers and their impact to the bilayer structure of stratum corneum lipid model membranes: neutron diffraction studies based on the example oleic acid. Biochim Biophys Acta 2011;1808:2798-2806.
22.
Engelbrecht TN, Demé B, Dobner B, Neubert RHH: Study of the influence of the penetration enhancer isopropyl myristate on the nanostructure of stratum corneum lipid model membranes using neutron diffraction and deuterium labelling. Skin Pharmacol Physiol 2012;25:200-207.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.